Kathleen McGinness is the director of in vitro pharmacology in the Stanley Center for Psychiatric Research at the Broad Institute. In this role, she works with Stanley Center geneticists and neuroscientists, along with researchers in platforms across the Broad, to help translate the emerging genetic data in psychiatric disease into validated disease targets. She works within the Therapeutics Discovery and Development Platform, leveraging the platform’s therapeutic expertise, with the goal of identifying therapeutic targets and initiating therapeutic programs to treat psychiatric disease.
McGinness brings expertise in drug discovery and therapeutic platform development to the Broad. Prior to joining the Broad in 2012, she was senior manager of research in the BioScience division at Baxter Healthcare in Cambridge, MA. In that role, she led and managed discovery programs to generate new hemophilia therapeutics. In addition, her group provided support for the clinical development of an aptamer therapeutic for the treatment of hemophilia. Prior to joining Baxter, she held positions with increasing levels of responsibility at Archemix Corp. in Cambridge. There, she led cross-functional discovery teams and a group of research scientists in the discovery, optimization, and characterization of nucleic acid aptamer therapeutics for a variety of disease indications. She also served as the alliance manager and project leader on therapeutic programs with large pharmaceutical company partners and led therapeutic platform development projects.
McGinness earned bachelor’s degrees in chemistry and psychology from the University of Maryland and a Ph.D. in chemistry from The Scripps Research Institute. She completed her postdoctoral training in the department of biology at MIT.